BMS buys stock in TCR-based cell therapies & bispecifics co.July 24, 2023 - “Immatics”, a Phase 1 biopharmaceutical company, in the discovery and development of T cell-redirecting cancer immunotherapies, announced that Bristol Myers Squibb (NYSE: BMY) has made a $35 million equity investment in the company
Bristol Myers Squibb purchased 2,419,818 ordinary shares in a private placement transaction at a subscription price per share of US$14.46
https://www.globenewswire.com/news-release/2023/07/24/2709406/0/en/Immatics-Announces-35-Million-Equity-Investment-from-Bristol-Myers-Squibb.html
https://immatics.com/our-pipeline/